Bullous pemphigoid associated with prodromal‐phase by repeated <scp>COVID</scp>‐19 vaccinations

Yamamoto, Sayumi; Koga, Hiroshi; Tsutsumi, Masahiro; Ishii, Norito; Nakama, Takekuni

doi:10.1111/1346-8138.16940

The Journal of Dermatology

2023

DOI: 10.1111/1346-8138.16940

|View full text |Cite

Bullous pemphigoid associated with prodromal‐phase by repeated COVID‐19 vaccinations

Sayumi Yamamoto,

Hiroshi Koga,

Masahiro Tsutsumi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Tozinameran

2024

Reactions Weekly

View full text Add to dashboard Cite

Tozinameran

2024

Reactions Weekly

View full text Add to dashboard Cite

An uncommon cause of dysphagia: esophagitis dissecans superficialis secondary to bullous pemphigoid after vaccination for SARS-CoV-2

Sánchez Moreno,

Fernández Carrasco,

Pinochet Almonacid

et al. 2024

Rev Esp Enferm Dig

View full text Add to dashboard Cite

Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review

Martora,

Battista,

Potestio

et al. 2024

Viruses

View full text Add to dashboard Cite

The COVID-19 pandemic has encouraged the rapid development and licensing of vaccines against SARS-CoV-2. Currently, numerous vaccines are available on a global scale and are based on different mechanisms of action, including mRNA technology, viral vectors, inactive viruses, and subunit particles. Mass vaccination conducted worldwide has highlighted the potential development of side effects, including ones with skin involvement. This review synthesizes data from 62 manuscripts, reporting a total of 142 cases of autoimmune blistering skin diseases (AIBDs) following COVID-19 vaccination, comprising 59 cases of pemphigus and 83 cases of bullous pemphigoid. Among the 83 bullous pemphigoid cases, 78 were BP, with additional cases including 2 oral mucous membrane pemphigoid, 1 pemphigoid gestationis, 1 anti-p200 BP, and 1 dyshidrosiform BP. The mean age of affected individuals was 72 ± 12.7 years, with an average symptom onset of 11 ± 10.8 days post-vaccination. Notably, 59% of cases followed vaccination with BNT162b2 (Pfizer-BioNTech), 51.8% were new diagnoses, and 45.8% occurred after the second dose. The purpose of our review is to analyze the cases of pemphigus and bullous pemphigoid associated with COVID-19 vaccination and to investigate the pathogenetic mechanisms underlying the new development or flare-up of these diseases in association with vaccination. Our results show that the association between COVID-19 vaccines and AIBDs is a possible event.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Bullous pemphigoid associated with prodromal‐phase by repeated COVID‐19 vaccinations

Cited by 4 publications

References 5 publications

Tozinameran

Tozinameran

An uncommon cause of dysphagia: esophagitis dissecans superficialis secondary to bullous pemphigoid after vaccination for SARS-CoV-2

Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review

Contact Info

Product

Resources

About